

MEDICOVER GENETICS

ONCOLOGY PORTFOLIO

oncosentia™



From molecular evidence to clinical insight

Medicover Genetics combines advanced molecular diagnostics, translational research, and precision oncology expertise to support clinical decision-making across the cancer care journey.

We work with healthcare professionals and research partners to generate relevant evidence and translate molecular insights into clinical applications.

HEREDITARY CANCER
Early detection of cancer risk

SOMATIC TUMOUR PROFILE / HAEMATOLOGICAL CANCER
Diagnosis and therapy identification

THERAPY SELECTION
Therapy guidance and resistance detection

MINIMAL RESIDUAL DISEASE
Risk stratification and disease progression monitoring

HEREDITARY CANCER

Comprehensive assessment of inherited genetic cancer susceptibility, enabling the identification of hereditary cancer predisposition syndromes and supporting personalised clinical management and family counselling.

- Non-invasive and safe for patients
- Detects inherited genetic variants associated with cancer predisposition syndromes
- Improves disease classification
- Helps identify prophylactic measures for cancer prevention, if applicable
- In some cases, identifies germline mutations associated with targeted therapies (e.g., PARP inhibitors)
- Improves patient clinical management and informs of familial cancer risk

SAMPLE	TAT
Buccal swab, EDTA blood	10-25 working days

- Single-gene analysis through comprehensive panels of up to 140 genes
- Coverage across breast and ovarian, colorectal, prostate, pancreatic, gastrointestinal, endocrine, renal, skin, CNS and haematological cancers among others
- Syndrome-focused testing such as HBOC, BRCA1/2-associated conditions and Lynch syndrome
- Full exonic coverage across genes tested for specific panels

SOMATIC TUMOUR PROFILE

Comprehensive tissue-based molecular profiling to support tumour characterisation, treatment selection and precision medicine across solid tumours.

- Comprehensive tumour molecular characterisation
- Detects genetic alterations associated with cancer development, relapse and therapy resistance
- Supports precision medicine by informing tailored treatment strategies based on tumour type and molecular profile
- Supports clinical management and improves disease classification

SAMPLE	TAT
FFPE tumour tissue	7-20 working days

- Comprehensive genomic profiling: up to 638 DNA-based genes and 22 RNA-based genes
- Includes MSI, TMB and HRD analysis
- Rearrangement and fusion analysis for clinically relevant alterations
- Tumour-specific profiling including mutation analysis, MSI assessment, and selected methylation analysis
- Applicable across diverse cancer types, including breast, colorectal, endometrial, glioblastoma, melanoma, NSCLC, ovarian, pancreatic, prostate, thyroid, and others

HAEMATOLOGICAL CANCER

Comprehensive molecular testing to support diagnosis, classification, prognostic assessment and clinical management of haematological malignancies.

- Supports diagnosis and molecular classification of haematological malignancies
- Identifies clinically relevant genetic alterations with diagnostic, prognostic and therapeutic significance
- Supports risk stratification and disease characterisation
- Assists treatment planning and clinical management
- Enables monitoring of molecular markers relevant to disease progression and response

SAMPLE	TAT
Peripheral blood, bone marrow aspirate or other validated specimen types, where applicable	Depending on test application

- Molecular profiling for selected haematological malignancies
- Assessment of clinically relevant genomic alterations associated with disease classification and prognosis
- Detection of mutations, copy number alterations and selected structural variants, where applicable
- Applications across myelodysplastic syndromes (MDS), leukaemias and other haematological neoplasms
- Integrated clinical interpretation to support decision-making

Currently available in Germany, globally available starting 2027.

LIQUID BIOPSY

Blood-based molecular testing supporting therapy selection, molecular reassessment and disease monitoring.

- Non-invasive and repeatable sampling
- Enables evaluation of tumour genetic profile during disease progression or therapy resistance
- Suitable when tissue biopsy is limited or unavailable
- Enables disease monitoring and risk stratification
- Supports treatment selection and assessment of therapy resistance
- Detects tumour heterogeneity and MRD

Therapy Selection

SAMPLE	TAT
Blood sample	6-9 working days

Identifies genetic characteristics of primary and metastatic tumours. It supports therapy selection, re-evaluates therapy resistance, and assesses biomarkers relevant to immunotherapy response.

- Pan-cancer profiling *(up to 222 genes with MSI and bTMB analysis)*
- Extended profiling *(80 genes with MSI analysis)*
- Tumour-specific panels across breast & gynaecological, colorectal, gastric, melanoma, NSCLC, pancreatic and prostate cancers *(23–48 genes)*
- Captures tumour heterogeneity by detecting alterations from both primary and metastatic sites
- Expands treatment options by linking findings to approved therapies and relevant clinical trials

Minimal Residual Disease (MRD)

SAMPLE	TAT
Blood sample	2-3 weeks

Intended for patients diagnosed with unresectable stage II/III non-small cell lung cancer (NSCLC) undergoing consolidation therapy and post treatment surveillance. This tumour-agnostic, plasma-informed assay provides patient sample-specific longitudinal ctDNA monitoring and binary ctDNA status (detected/not detected), supporting patient risk stratification.

- Tumour-agnostic, plasma-informed ctDNA assessment
- Supports longitudinal monitoring without requiring tumour tissue
- Provides additional molecular information for multidisciplinary evaluation alongside imaging and clinical findings

PHARMACOGENOMICS (PGx)

Genetic testing to support personalised treatment decisions by identifying genetic variants that may influence drug response, efficacy and safety.

- Supports personalised treatment selection
- Identifies genetic factors associated with drug metabolism and response
- Helps optimise dosing strategies where clinically relevant
- Supports reduction of adverse drug reactions and treatment-related toxicity
- Enables more informed prescribing decisions

SAMPLE	TAT
Buccal swab, EDTA blood	Depending on test application

- Analysis of clinically relevant pharmacogenomic markers associated with drug metabolism pathways
- Assessment of variants influencing efficacy, safety and tolerability of selected therapies
- Evidence-based interpretation aligned with recognised pharmacogenomic recommendations and guidelines
- Applicable across multiple therapeutic areas where pharmacogenomic information may inform clinical management

Precision oncology solutions across the cancer care continuum

Medicover Genetics provides a broad precision oncology portfolio to support clinicians in addressing clinical questions and informing decisions across the cancer care continuum.

UNIQUE FEATURES

Immunotherapy eligibility

Immunotherapy biomarkers, such as TMB and MSI, are assessed. FDA/EMA approved immunotherapy options can be available depending on the type of tumour.

Tumour Mutational Burden (TMB)

TMB is an independent, tumour-agnostic biomarker. It measures the total number of mutations per megabase and identifies patients eligible for specific immunotherapy treatment.
Blood TMB (bTMB) is an emerging biomarker based on analysis of circulating tumour DNA (ctDNA) released from the tumour into the blood circulation.

Somatic Tumour | Therapy Selection

Microsatellite Instability (MSI)

Identifies mutation frequency within satellites (short, repeated sequences of DNA). It can have therapeutic and prognostic value for patients with solid tumours who present high MSI status.

Somatic Tumour | Therapy Selection

Clinical trials eligibility

Tested genes and genomic signatures serve as selection criteria in ongoing clinical trials.

Somatic Tumour | Therapy Selection

Clinically relevant genes

The genetic alterations tested are included in clinical practice guidelines and are recommended by professional bodies such as NCCN, ESMO and ASCO.

Somatic Tumour | Therapy Selection | Hereditary Cancer

Technological advantages

The tests are based on technology platforms validated for their precision and accuracy.

Somatic Tumour | Therapy Selection | Hereditary Cancer

Clinical interpretation of results

Detailed interpretation of the results on the report, guiding healthcare providers towards the most appropriate therapeutic strategies for their patients.

Somatic Tumour | Therapy Selection | Hereditary Cancer

Novel technology for MRD detection

Enables tumour-agnostic, plasma-informed MRD detection. Allows longitudinal monitoring for disease progression throughout the patient's treatment journey and clinical surveillance for risk stratification.

MRD

Homologous Recombination Deficiency (HRD)

Assesses genomic instability caused by defects in homologous recombination DNA repair mechanisms. HRD can have predictive value for patients with solid tumours and may support identification of individuals who could benefit from PARP inhibitor-based therapies.

Somatic Tumour

WHY MEDICOVER GENETICS FOR ONCOLOGY

Broad precision oncology portfolio	Germline and somatic testing for hereditary cancer risk assessment, tumour profiling, treatment selection and disease monitoring, complemented by histopathology and genetic counselling.
Advanced liquid biopsy expertise	Liquid biopsy applications for treatment guidance and minimal residual disease (MRD) monitoring in defined clinical settings.
Research and validation	Development and validation of molecular approaches for oncology, based on clinically relevant evidence and professional guidelines.

ABOUT MEDICOVER GENETICS

Medicover Genetics enables the implementation of genetics in routine healthcare through an integrated model of specialised clinical services and laboratory solutions. With more than 27 years of clinical genetics experience, the company supports healthcare systems, laboratories, and clinicians worldwide through innovative and translational genetic solutions across oncology, reproductive health, rare diseases, and precision medicine. Operating through CAP, CLIA and ISO 15189 accredited laboratories, Medicover Genetics delivers clinically validated solutions that focus on caring for patients at every stage of their clinical pathway.

Medicover Genetics is part of Medicover, an international healthcare and diagnostic services company listed on Nasdaq Stockholm.

CONTACT US

www.medicover-genetics.com
info.genetics@medicover.com

Germany
Lochhamer Str. 29, 82152 Planegg

Cyprus
Neas Engomis 31, 2409 Nicosia

Greece
120 Vas. Sofias, 11526 Athens

MEDICOVER GENETICS